Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Newron Pharmaceuticals
Newron Pharmaceuticals
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Safinamide to be made available in Asia for Parkinson's
Meiji Seika and Eisai enter into a collaboration for the development and commercialisation of safinamide in Parkinson’s disease for Japan and Asia
FDA approves Xadago for Parkinson’s patients
Xadago (safinamide) is first NCE approved in the USA for PD patients with motor fluctuations in a decade
Pharmaceutical
Newron starts operations in New Jersey, US
Two senior executives join the company and will be located in Morristown, New Jersey
Regulatory
Parkinson’s disease – safinamide
The effectiveness of dopamine agonist drugs to treat Parkinson\'s disease decreases over time as more and more dopamine-producing cells die
Research & Development
Newron receives €2.5m grant from Wellcome Trust
To fund clinical trial for amyotrophic lateral sclerosis (ALS)
Finance
Newron to acquire NeuroNova for €15.4m
Gains two Phase II compounds for progressive neurogenerative diseases
Research & Development
Newron and Zambon enter into a new €5m agreement for safinamide
Zambon will make a total investment in Newron of €20m
Subscribe now